Cardiac manifestations of PRKAG2 mutation. by Banankhah, Pooya et al.
UCLA
UCLA Previously Published Works
Title


















eScholarship.org Powered by the California Digital Library
University of California
CASE REPORT Open Access
Cardiac manifestations of PRKAG2 mutation
Pooya Banankhah1, Gregory A. Fishbein2, Anthony Dota3 and Reza Ardehali4*
Abstract
Background: The Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) cardiac syndrome is
characterized by glycogen accumulation in the cardiac tissue. The disease presents clinically with hypertrophic
cardiomyopathy (HCM), and it is often associated with conduction abnormalities.
Case presentation: A 23 year-old female with history of Wolff-Parkinson-White (WPW) and HCM presented for
evaluation after an episode of Non-ST Elevation Myocardial Infarction (NSTEMI). The patient was found to have severe
coronary bridging on angiography and underwent an unroofing of the left anterior descending artery (LAD). Due to
the constellation of symptoms, the patient underwent genetic testing and a cardiac muscle biopsy. Genetic testing
was significant for an Arg302Gln mutation in the PRKAG2 gene. Cardiac tissue biopsy revealed significant myocyte
hypertrophy and large vacuoles with glycogen stores.
Conclusion: The pathologic and genetics findings of our patient are consistent with PRKAG2 syndrome. Patients
presenting with conduction abnormalities and suspected HCM should be considered for genetic testing to identify
possible underlying genetic etiologies.
Keywords: Cardiovascular pathology, Hypertrophic cardiomyopathy, PRKAG2 cardiac syndrome, Wolff-Parkinson-white
syndrome
Background
HCM is a heterogeneous cardiovascular disease with the
prevalence of 1 in 500 in the general population [1].
Clinical diagnosis of HCM requires a hypertrophied,
non-dilated left ventricle without evidence of any other
cardiac or systemic disease that could produce the
observed hypertrophy [1]. Sarcomere protein gene muta-
tions have been associated with up to 60% of familial or
sporadic cases of HCM [2]. However, recent studies have
led to identification of non-sarcomeric causes, including
inborn errors of metabolism, neuromuscular diseases,
mitochondrial diseases, malformation syndromes, and
drug reactions that mimic HCM [2]. PRKAG2 cardiac
syndrome is an autosomal dominant metabolic heart dis-
ease characterized by left ventricular hypertrophy (LVH),
progressive conduction abnormalities, and ventricular
pre-excitation. The prevalence of PRKAG2 syndrome is
0.23–1% in patients with suspected HCM [3].
Cardiomyopathies caused by glycogen storage diseases
including PRKAG2 mutations are distinguished from
other types of HCM by the formation of glycogen filled
vacuoles in myocytes [4]. The glycogen accumulation is
often associated with an eccentric pattern of hypertrophy
and conduction abnormalities that characterize the
PRKAG2 syndrome. This case report describes the clinical
presentation and pathologic findings of a patient with a
PRKAG2 mutation who presented with angina and
palpitations.
Case presentation
A 23 year-old female with history of WPW, HCM, and
pseudotumor cerebri was referred to our center for fur-
ther evaluation and treatment of persistent angina. The
patient had a history of WPW syndrome, for which a
catheter ablation had previously been performed. The
patient had been experiencing frequent angina both at
rest and with exertion. During hospitalization at the re-
ferring facility for a ventriculoperitoneal shunt repair,
the patient suffered a NSTEMI and was immediately
transferred to our center.
On admission, electrocardiogram showed normal sinus
rhythm with left atrial enlargement, left ventricular
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hypertrophy with repolarization abnormalities, and an
incomplete right bundle branch block. The patient’s
echocardiogram revealed a dynamic left ventricle with
an ejection fraction of 70–75% and end-diastolic septal
thickness of 2.2 cm without presence of systolic anterior
motion of mitral valve. A cardiac magnetic resonance
imaging study confirmed prominent hypertrophy in the
apical and septal regions. Given her persistent angina, a
coronary angiogram was performed that revealed severe
coronary bridging with compression of the proximal to
mid LAD with near complete compression of all the
septal perforator branches. In addition, the left ventricle
was noted to be spade-shaped with substantial
hypertrophy in mid to apical regions.
The presence of HCM in the setting of previous WPW
syndrome raised suspicion for an underlying genetic dis-
order. In addition, patient reported a family history of an
uncle with WPW. Genetic testing using Illumina next
generation sequence analysis revealed a missense
Arg302Gln mutation in the PRKAG2 gene, confirming
the clinical diagnosis of glycogen storage cardiomyopathy.
This missense heterozygous mutation on exon 7 replaces
arginine with glutamine at codon 302 of the PRKAG2
gene. The PRKAG2 gene consists of 560 amino acids with
a molecular mass of approximately 63kd [5]. The patient
was also found to have a heterozygous CACNB2 mutation
on exon 4, which is of unclear clinical significance.
The patient underwent an unroofing of the LAD and a
radical extended myomectomy of septal muscle through a
left ventricular apical approach. The atrial and ventricular
muscles were noted to have significantly increased
thickness during the surgery, which was previously ob-
served on the echocardiogram. The patient was also found
to have an abnormal papillary muscle attached to the an-
terior mitral leaflet, which was surgically resected. Post--
surgical transesophageal echo showed a pseudo normal
diastolic left ventricular filling. There were no post-
operative complications. At 3-month follow up, the
patient remained symptom-free with significantly
improved exercise tolerance.
Histology of the myocardial tissue revealed sub-
sarcolemmal glycogen storage on Hematoxylin and Eosin
(H&E) stain as well as Toluidine Blue stain (Fig. 1). The
vast cytoplasmic glycogen accumulation was further con-
firmed on electron microscopy (Fig. 2). Glycogen storage
in the tissue was also noted by a positive Periodic
acid–Schiff (PAS) stain and digestion of glycogen with
diastase. These findings further confirmed the clinical
diagnosis.
Discussion and conclusions
A genetic mutation linking familial HCM and WPW
mapping to chromosome 7 band q3 was first described
in 1995 [6]. This locus was later identified as the gene
PRKAG2, which encodes for the y2 regulatory subunit
of AMP-activated protein kinase (AMPK) [5]. AMPK is
a heterotrimeric complex comprising a catalytic subunit
(α) and two regulatory subunits (β and y) [7]. Activation
of AMPK during acute low-energy states phosphorylates
several downstream substrates and switches off ATP-
consuming pathways such as glycogen, cholesterol and
fatty acid synthesis. At the same time, AMPK activates
ATP-producing pathways such as fatty acid oxidation,
and it increases glucose uptake in cells [7, 8]. The
Fig. 1 1 μm thick section stained with Toluidine blue. Arrows indicate
intracellular glycogen accumulation both in vacuoles (white) and
sub-sarcolemmal (black)
Fig. 2 Transmission electron microscopy of the frozen endomyocardial
biopsy tissue. There is marked cytoplasmic glycogen accumulation and
occasional myelin bodies of various sizes. Gly = glycogen; MB =myelin
body; Myo =myofibril; Mit =mitochondria; Col = extracellular collagen;
black arrows denote cell membrane
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mechanism by which PRKAG2 mutations lead to
impaired glucose metabolism and excess glycogen stor-
age in human cells is not well defined [9]. It has been
proposed that early in the disease course the myocardial
glucose uptake is elevated due to AMPK activation.
However in advanced disease stages, AMPK may be sup-
pressed by a negative feedback mechanism from the
accumulated glycogen [9].
PRKAG2 syndrome leads to pronounced enlargement
of myocytes with frequent intracellular vacuoles filled with
glycogen. This is in contrast to sarcomeric gene muta-
tions, which pathognomonically present with myofibrillar
disarray on microscopy [4]. This distinct pathology is
likely responsible for the unique clinical manifestations of
the disease. Other case reports of Arg302Gln mutations
show a similar pattern of asymmetric HCM and the pres-
ence of an accessory pathways in patients with a family
history of HCM as well as patients with de novo muta-
tions [10]. There are reports of patients with this mutation
who present with cardiac arrest and require the implant-
ation of a defibrillator [10]. However, no previous reports
include the presence of coronary bridging, which we
found on angiography.
PRKAG2 syndrome often manifests at a young adult age
with a wide spectrum of presentations. A 12-year study of
PRKAG2 syndrome in 45 mutations carriers from three
families showed the mean initial age of presentation is 24.
The most frequent initial presentations included palpita-
tions (48%), syncope (28%), and pre-syncope (15%). How-
ever, the spectrum of presenting symptoms included chest
pain, heart failure, myalgia, and epilepsy [11].
Evaluation of PRKAG2 patients by EKG frequently
shows a short PR interval and delta waves. On echocar-
diogram, patients with PRKAG2 syndrome have been
noted to have LVH with an eccentric distribution [11].
The natural history of PRKAG2 mutations reveals a
slowly progressive, occasionally massive, increase in wall
thickness in the majority of patients [11]. These findings
are in contrast with sarcomere gene mutation forms of
HCM, in which the myocardium undergoes a gradual
decrease in hypertrophy with increasing age [12]. In
addition, patients with sarcomeric gene mutations usu-
ally have an asymmetrical pattern of hypertrophy with
predilection for the intraventricular septum [13]. With
progression of the disease, PRKAG2 syndrome often
evolves into a phase characterized by systolic dysfunc-
tion and left ventricular dilation. These features resem-
ble dilated cardiomyopathy and can subsequently
progress into heart failure [14].
PRKAG2 mutations have been linked to arrhythmias,
particularly WPW syndrome. The underlying molecular
mechanism for the arrhythmias is not entirely known,
but it has been associated with the glycogen accumula-
tion in the tissue. This association was elucidated in a
study, which showed that inhibition of glycogen content
accumulation in cardiomyocytes can effectively suppress
arrhythmias in transgenic mice [14]. A different study
suggested an alternative mechanism based on the obser-
vation that mutations in PRKAG2 lead to thinned and
stretched annulus fibrosis, which is disrupted at the
atrioventricular junction. These findings, along with the
lack of identification of a histologically defined bypass
tract, have suggested that the disruption in annulus fi-
brosis may be responsible for pre-excitation syndrome
seen in PRKAG2 mutations [15].
It is important for clinicians to recognize various gen-
etic syndromes and their unique clinical presentations in
patients with suspected HCM. Patients presenting with
features of HCM and conduction abnormalities may re-
quire further investigation into a unifying underlying
genetic etiology for their disease presentation. This case
highlights the utility of genetic testing in in diagnosing a
patient with PRKAG2 syndrome, which was further con-
firmed by heart tissue biopsy. The CARE guidelines were
followed in reporting this case.
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